RESUMEN
PURPOSE: To explore the effect of dexmedetomidine combined with flurbiprofen axetil on postoperative analgesia and immune function in patients with lung cancer after radical operation. METHODS: 60 lung cancer patients undergoing open chest radical surgery were selected and randomly divided into D & F Group (dexmedetomidine combined with flurbiprofen axetil) and F Group (flurbiprofen axetil), with 30 cases in each group. Before induction of general anesthesia, Group F was administered intravenous flurbiprofen axetil, and in D & F group, dexmedetomidine and erfuorbiprofen axetil were injected. RESULTS: At T2 (intubation) and T3 (extubation), map and HR in D & F group were significantly lower than those in F group (p<0.05). The extubation quality score of D & F group was significantly lower than that of F group (p<0.05). At 6 h and 12 h after operation, visual analogue scale (VAS) score and Bruggrmann comfort scale (BCS) score of D & F group were significantly lower than that of F group (p<0.05). The dosage of sufentanil and the times of pressing analgesia pump in group D & F were significantly less than those in group F (p<0.05). NK cells, CD3 + T cells and CD4 + / CD8 + in the D & F group were significantly higher than those in F group at 12h, 24h, 48 h and 1 week after operation (p<0.05). CONCLUSIONS: Flurbiprofen axetil can improve postoperative pain, but combined with dexmedetomidine better effect, postoperative comfort and immune function of patients were significantly improved.
Asunto(s)
Analgésicos no Narcóticos/administración & dosificación , Dexmedetomidina/administración & dosificación , Flurbiprofeno/análogos & derivados , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/cirugía , Dolor Postoperatorio/tratamiento farmacológico , Adulto , Anciano , Antiinflamatorios no Esteroideos , Combinación de Medicamentos , Femenino , Flurbiprofeno/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
OBJECTIVE: To investigate the effect of penehyclidine hydrochloride (PHC) in a rat model of renal injury induced by hemorrhagic shock and lipopolysaccharides (LPS). METHODS: Forty-five healthy Wistar rats were randomized into sham operated group, model group, and 3 penehyclidine hydrochloride (PHC) dose (1, 2 and 3 mg/kg) groups (PHC1, PHC2, and PHC3 groups, respectively). The arterial blood samples were collected to determine the concentrations of serum tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), interleukin-1 (IL-1), urine creatinine (Cr) and blood urine nitrogen (BUN), and the renal tissues were collected to measure the expressions of ICAM-1 and nuclear factor-κB (NF-κB) and observe the pathological changes. RESULTS: TNF-α, IL-8, IL-1, Cr, BUN, ICAM-1 and NF-κB in the 3 PHC groups were significantly lower than those in the model group (P<0.05). TNF-α, IL-8, IL-1, Cr and BUN were significantly lower in PHC1 (P<0.05) than in the PHC2 and PHC3 groups, and ICAM-1 and NF-κB were similar between 3 PHC groups (P>0.05). Compared with the model group, the 3 PHC groups showed lessened pathological changes in the renal tubules. CONCLUSION: PHC has protective effects against renal injury induced by hemorrhagic-endotoxin shock in rats, and treatment with 1 mg/kg PHC produces the most significant protective effect.